Two conversations. Two different vantage points on agentic AI in drug development.
Ari Caroline, Weave’s Co-founder and Chief Strategy Officer, will be at the AI Agent Conference on May 5, contributing to both.
2:05 PM
Agentic AI in Drug Development: From Discovery to Approval
Ari joins Saira Mueller (Morning Brew) and Umut Eser (Johnson & Johnson) to explore how agentic systems are showing up across the lifecycle—from early discovery through approval.
2:25 PM
Getting it Right: Applying Novel Agentic AI Capabilities in a High-Stake, High-Complexity Drug Development Setting
Ari will host a panel with Andrew Robertson (Takeda), Vada Perkins (Boehringer Ingelheim), and Viral Vyas (Bristol Myers Squibb), focused on what it actually takes to apply these systems in real, high-stakes environments.
From big-picture potential to practical application—both conversations stay grounded in what teams are working through right now.
